ISSN 1016-5169 | E-ISSN 1308-4488
Archives of the Turkish Society of Cardiology
Clinical effectiveness of ranolazin [Turk Kardiyol Dern Ars]
Turk Kardiyol Dern Ars. 2016; 44(3): 13-18 | DOI: 10.5543/tkda.2016.84827

Clinical effectiveness of ranolazin

Necla Özer
Hacettepe Üniversitesi Tıp Fakültesi Kardiyoloji Anabilim Dalı, Ankara

Despite currently prevalent medical, and interventional treatment methods ischemia still continues to be an import ant health problem. Inhibition of late sodium current into cells has emerged as a new target in thetreatment of ischemia, and ranozolin is the most important drug developed to this end. Ranozolin which displays its antianginal effect without effecting heart rate, and blood pressure is recommended as a treatment alternative with proved efficancy in addition to conventional treatment. In this paper, we have attempted to summarize clinical studies which investigated effectiveness of ranozolin.

How to cite this article
Necla Özer. Clinical effectiveness of ranolazin. Turk Kardiyol Dern Ars. 2016; 44(3): 13-18

Corresponding Author: Necla Özer, Türkiye
Manuscript Language: Turkish

Journal Metrics

Journal Citation Indicator: 0.18
CiteScore: 1.1
Source Normalized Impact
per Paper:
SCImago Journal Rank: 0.348

Quick Search

Copyright © 2023 Archives of the Turkish Society of Cardiology

Kare Publishing is a subsidiary of Kare Media.